Project Grant HT94252410654
Award Date
7/1/24
Completion Date
6/30/27
Dollars Obligated
$1.2M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The University of Queensland received a $1,120,707 project grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) to develop a first-in-class calcium channel inhibitor for the treatment of advanced metastatic prostate cancers resistant to next-generation antiandrogen therapy. The award has a performance period from July 1, 2025, to June 30, 2028, and aims to transform healthcare for military service members, veterans, and the broader public...
This $1,214,449 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The awardee, Queensland University of Technology (QUT) in Australia, will lead this 3-year research effort from September 1, 2024 to August 31, 2027. QUT is a prominent...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
The Defense Health Agency awarded a $744,997 Project Grant to the University of Queensland in Australia under the Military Medical Research and Development program (CFDA 12.420). This grant, titled "DISCOVERING THERAPEUTIC VULNERABILITIES OF CIRCULATING MELANOMA CLUSTERS," provides funding for the university to conduct cutting-edge biomedical research on melanoma from June 1, 2024 through May 31, 2027. The University of Queensland, a leading research institution in Australia, has an...
This Project Grant award of $231,009.44 from the Defense Health Agency under the Military Medical Research and Development Program (CFDA 12.420) supports research at the University of Adelaide in Australia to understand heterogeneity and improve the precision of prostate cancer clinical outcomes. The 3-year project, which runs from September 1, 2023 to August 31, 2026, aims to advance scientific understanding and develop new treatments related to prostate cancer, a key health condition affecting...
This federal Project Grant award of $563,707.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Queensland in Australia to predict early-stage melanoma at high risk of recurrence through multiomics profiling. The grant, awarded on September 1, 2025, aims to transform healthcare for military service members, veterans, and the public through innovative biomedical research. The University of Queensland, a...
The University of Adelaide in Australia was awarded a $1,005,845 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from September 2022 through September 2025 to exploit prostate cancer metabolic dependencies to develop new therapeutics and circulating prognostic and predictive biomarkers. The Military Medical Research and Development program supports basic, applied, and...
The U.S. Defense Health Agency has awarded a $367,622 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to St. Vincent's Institute of Medical Research, a foreign-owned non-profit organization based in Australia. The grant supports a 2-year research project focused on studying the reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer. The research aims to transform healthcare for military service members and the broader public...
This federal Project Grant award of $1,156,726.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by the University of Queensland (UQ) in Australia. The objective of the research project is to predict early-stage melanoma at high risk of recurrence through multiomics profiling. The award has a performance period from September 1, 2025 to August 31, 2028. UQ, a leading Australian research university, has an extensive...
The U.S. Defense Health Agency awarded a $437,975 Project Grant to the University of New South Wales, doing business as The University of NSW, to conduct research on "TARGETING THE NOVEL LONG NONCODING RNA PRKCQ-AS1 FOR CANCER THERAPY". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform healthcare for U.S. Service Members and the public. The funded research aims...